# EDGAR Filing Document

**Accession Number:** 0001757097
**File Stem:** 0000950103-23-001372
**Filing Date:** 2023-1
**Character Count:** 4449
**Document Hash:** 7946bc33205bb56d9307ce48345e3c9d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-23-001372.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0000950103-23-001372

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230130

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Centogene N.V.
- **CENTRAL INDEX KEY:** 0001757097
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39124
- **FILM NUMBER:** 23568195

**BUSINESS ADDRESS:**
- **STREET 1:** AM STRANDE 7
- **CITY:** ROSTOCK
- **STATE:** 2M
- **ZIP:** 18055
- **BUSINESS PHONE:** 49 30 2130 00325

**MAIL ADDRESS:**
- **STREET 1:** AM STRANDE 7
- **CITY:** ROSTOCK
- **STATE:** 2M
- **ZIP:** 18055

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Centogene B.V.
- **DATE OF NAME CHANGE:** 20181025

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the date of January 30, 2023

Commission File Number 001-39124

<br> **Centogene N.V.**<br> (Translation of registrant's name into English)

**Am Strande 7<br> 18055 Rostock**

**Germany**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F..X.. Form 40-F.....

<br> Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

**Centogene N.V.**

On January 30, 2023, Centogene N.V. announced an Executive Appointment.

A copy of the announcement is attached hereto as Exhibit 99.1.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 30, 2023

---

| | | |
|:---|:---|:---|
| CENTOGENE N.V. | CENTOGENE N.V. | CENTOGENE N.V. |
| By: | /s/ Jose Miguel Coego Rios | /s/ Jose Miguel Coego Rios |
|  | Name: | Jose Miguel Coego Rios |
|  | Title: | Chief Financial Officer |

---

**Exhibit Index**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description of Exhibit</u>** |
| 99.1 | Announcement dated January 30, 2023 |

---

## Exhibit 99.1

**Exhibit 99.1**

***CENTOGENE Announces Executive Appointment***

**CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, January 30, 2023** - Centogene N.V. (the "Company") (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that Prof. Peter Bauer, M.D., the Company's Chief Medical and Genomic Officer, has been appointed to the Management Board of Centogene N.V. as of January 24, 2023, to be confirmed at the Company's next General Meeting of Shareholders. Prof. Bauer has also been appointed as Managing Director of the subsidiary Centogene GmbH.

Prof. Bauer has been serving as CENTOGENE's Chief Medical and Genomic Officer since 2022. In this role, he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments—turning medical questions into complete and fast analytical processes and ensuring that medically-driven results are brought to clinicians and patients immediately. Prof. Bauer originally joined CENTOGENE in 2016 and has since held a variety of management positions within the Company, including operations as well as innovation and research related roles. Prof. Bauer received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Prof. Bauer has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.

**Contact:**

**CENTOGENE**

Ben Legg

Corporate Communications

<u>Press@centogene.com</u>

Lennart Streibel

Investor Relations

<u>IR@centogene.com</u>